Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.07. | Milan: Philogen on the rise | 2 | Teleborsa | ||
08.07. | Milan: Downbeat day for Philogen | - | Teleborsa | ||
05.07. | EMA validates Philogen and Sun Pharma's MAA for melanoma | 2 | Pharmaceutical Technology | ||
04.06. | Philogen and Sun Pharma seek EMA approval for melanoma therapy | 3 | Pharmaceutical Technology | ||
20.02. | Philogen S.p.A.: Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma | 353 | GlobeNewswire (Europe) | FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or... ► Artikel lesen | |
05.12.23 | Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities | 440 | GlobeNewswire (Europe) | SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted... ► Artikel lesen | |
04.12.23 | Philogen S.p.A.; Blue Earth Diagnostics: Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors | 424 | GlobeNewswire (Europe) | Novel ultra-high affinity ligand OncoFAP targets Fibroblast Activation Protein (FAP), associated with a variety of solid tumorsLicensing agreement between Philochem and Blue Earth Diagnostics, one of... ► Artikel lesen | |
16.10.23 | Philogen S.p.A.: Nidlegy Phase III PIVOTAL trial meets the study's primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma | 432 | GlobeNewswire (Europe) | Intratumoral Nidlegy followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone
PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
WINDTREE THERAPEUTICS | 8,220 | +149,09 % | Pre-market Movers: Windtree Therapeutics, Carbon Revolution, BurgerFi International, Everi Holdings, Nature's Miracle Holding | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Windtree Therapeutics, Inc. (WINT) is up over 117%... ► Artikel lesen | |
ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
TARSUS PHARMACEUTICALS | 25,010 | -11,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
IMMUNOVANT | 29,100 | +4,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 | Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 11,550 | +10,10 % | DelveInsight Business Research, LLP: Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche | The landscape of bispecifics and trispecifics antibodies is rapidly evolving, driven by advancements in immunotherapy and targeted cancer treatments. Biotech companies are racing to develop... ► Artikel lesen | |
EVOTEC | 8,680 | -0,23 % | Evotec Aktie: Analysten sehen Wendepunkt trotz Kursrückgang | Die Evotec-Aktie verzeichnete in den letzten Handelstagen einen deutlichen Kursrückgang und notierte zuletzt bei 8,61 Euro. Trotz des aktuellen Abwärtstrends zeigen sich Analysten für die Zukunft optimistisch.... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 48,130 | +7,63 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
APOGEE THERAPEUTICS | 49,950 | +2,65 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results | Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept... ► Artikel lesen | |
BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
KINIKSA PHARMACEUTICALS | 26,120 | +0,81 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $405 - $415 million -- Abiprubart... ► Artikel lesen | |
CG ONCOLOGY | 33,030 | +0,12 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates | Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient... ► Artikel lesen | |
IMMUNOME | 16,510 | +2,99 % | Immunome Reports First Quarter 2024 Financial Results and Provides Business Update | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial... ► Artikel lesen | |
DYNE THERAPEUTICS | 44,590 | +4,43 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease | WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |